United Therapeutics gets another FDA approval for pulmonary hypertension therapy
United Therapeutics (NASDAQ: UTHR) has received another Food and Drug Administration approval for Tyvaso more than a decade after the agency first approved the therapy for treatment of pulmonary arterial hypertension.
The FDA approved a supplemental new drug application for the use of Tyvaso Inhalation Solution, an inhaled form of the drug trepostinil, to increase exercise ability in patients with pulmonary hypertension resulting from interstitial lung disease (PH-ILD), United Therapeutics said… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 1, 2021 Category: Health Management Authors: Rebecca Cooper Source Type: news
United Therapeutics gets another FDA approval for pulmonary hypertension therapy
United Therapeutics (NASDAQ: UTHR) has received another Food and Drug Administration approval for Tyvaso more than a decade after the agency first approved the therapy for treatment of pulmonary arterial hypertension.
The FDA approved a supplemental new drug application for the use of Tyvaso Inhalation Solution, an inhaled form of the drug trepostinil, to increase exercise ability in patients with pulmonary hypertension resulting from interstitial lung disease (PH-ILD), United Therapeutics said… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 1, 2021 Category: Biotechnology Authors: Rebecca Cooper Source Type: news
United Therapeutics gets another FDA approval for pulmonary hypertension therapy
United Therapeutics (NASDAQ: UTHR) has received another Food and Drug Administration approval for Tyvaso more than a decade after the agency first approved the therapy for treatment of pulmonary arterial hypertension.
The FDA approved a supplemental new drug application for the use of Tyvaso Inhalation Solution, an inhaled form of the drug trepostinil, to increase exercise ability in patients with pulmonary hypertension resulting from interstitial lung disease (PH-ILD), United Therapeutics said… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 1, 2021 Category: Health Management Authors: Rebecca Cooper Source Type: news
Machine-learning predicts complications from CT-guided biopsy
Machine-learning models can predict whether a CT-guided transthoracic biops...Read more on AuntMinnie.comRelated Reading:
AI reduces variability in breast density reporting
Top 10 questions to ask when buying radiology AI software
PET/CT guidance offers valuable approach to lung biopsies
CT quantifies COVID-19 severity, ongoing conditions
CT textures predict interstitial lung disease survival (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 15, 2021 Category: Radiology Source Type: news
Tocilizumab Scores FDA Approval for SSc-ILD Tocilizumab Scores FDA Approval for SSc-ILD
Tocilizumab is the first biologic to be approved by the agency for adults with systemic sclerosis –associated interstitial lung disease, a rare, potentially life-threatening condition.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 8, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news
Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no cure. ...
Source: Roche Investor Update - March 5, 2021 Category: Pharmaceuticals Source Type: news
Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no cure. ...
Source: Roche Media News - March 5, 2021 Category: Pharmaceuticals Source Type: news
Study Clarifies Who Gets Post –COVID-19 Interstitial Lung Disease Study Clarifies Who Gets Post –COVID-19 Interstitial Lung Disease
A study of post –COVID-19 patients in the UK who developed severe lung inflammation after they left the hospital may provide greater clarity on which patients are most likely to have persistent lung dysfunction.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - March 4, 2021 Category: Emergency Medicine Tags: Infectious Diseases News Source Type: news
Tocilizumab May Improve Lung Function in Early Systemic Sclerosis Tocilizumab May Improve Lung Function in Early Systemic Sclerosis
Treatment with tocilizumab could stabilize or improve lung function in people with early interstitial lung disease associated with systemic sclerosis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 19, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news
Lung Disease Raises Mortality Risk in Older RA Patients Lung Disease Raises Mortality Risk in Older RA Patients
RA-associated interstitial lung disease has been associated with worse survival rates as well as reduced quality of life, functional impairment, and increased health care use and costs.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 28, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news
FDA grants priority review to Roche ’s Esbriet (pirfenidone) for unclassifiable interstitial lung disease
Basel, 21 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental New Drug Application (sNDA) and granted Priority Review for Esbriet® (pirfenidone) for the treatment of unclassifiable interstitial lung disease (UILD). The FDA is expected to make a decision on approval by May 2021.“Since its US approval, Esbriet has become a standard of care for people living with idiopathic pulmonary fibrosis. However, significant unmet need remains in fibrotic lung diseases, including unclassifiable interstitial lung disease (UILD),” ...
Source: Roche Investor Update - January 21, 2021 Category: Pharmaceuticals Source Type: news
Inhaled Treprostinil Beneficial in Pulmonary Hypertension
Exercise capacity improved, clinical worsening reduced for patients with pulmonary HTN due to interstitial lung disease (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - January 14, 2021 Category: Respiratory Medicine Tags: Cardiology, Pharmacy, Pulmonology, Journal, Source Type: news
Inhaled Treprostinil Beneficial in Pulmonary Hypertension
THURSDAY, Jan. 14, 2021 -- Inhaled treprostinil improves exercise capacity in patients with pulmonary hypertension due to interstitial lung disease, according to a study published online Jan. 13 in the New England Journal of Medicine.
Aaron Waxman,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 14, 2021 Category: Pharmaceuticals Source Type: news
CT helps clinicians predict emphysema progression
The pattern of parenchymal emphysema on baseline CT scans forecasts progression...Read more on AuntMinnie.comRelated Reading:
Deep-learning algorithm detects free air on CT images
Machine learning boosts chest CT's performance
CT textures predict interstitial lung disease survival
COVID-19 patients face higher risk of barotrauma
CT helps predict TAVR outcomes (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 18, 2020 Category: Radiology Source Type: news
